Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 15/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31148927 | 0.81 | P2RX4 (0.47) | P2RX4P2RX1P2RX3MAPTSMN1; SMN2 | |
| SCHEMBL1423685 | 0.81 | P2RX4 (0.47) | P2RX4P2RX1P2RX3MAPTSMN1; SMN2 | |
| SCHEMBL3969789 | 0.77 | P2RX4 (0.44) | P2RX4P2RX1P2RX3MAPTSMN1; SMN2 | |
| SCHEMBL31067286 | 0.73 | KDM4E (0.55) | P2RX4P2RX1MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL47007 | 0.73 | KDM4E (0.55) | P2RX4P2RX1MAPTSMN1; SMN2NPSR1 | |
| Methoxymethane SCHEMBL28814461 | 0.72 | AHR (0.46) | P2RX4 | |
| Hydrogen Sulfide SCHEMBL28845788 | 0.71 | KDM4E (0.53) | P2RX4P2RX1MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL18318143 | 0.71 | L3MBTL1 (0.52) | SMPD1 | |
| SCHEMBL4453866 | 0.70 | P2RX4 (0.46) | P2RX4P2RX1P2RX3MAPTSMN1; SMN2 | |
| SCHEMBL10090153 | 0.70 | SMPD1 (0.47) | P2RX4SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2049507-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | P2RX4 4023/4885P2RX1 3012/4885P2RX3 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.